Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes:A meta-analysis
作者机构：Department of Endocrinology and MetabolismPeking University People's HospitalBeijing 100044China
出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)
年 卷 期：2023年第14卷第10期
页 面：1573-1584页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Beijing Natural Science Foundation,No.7202216 National Natural Science Foundation of China,No.81970698 and No.81970708
主 题：Chiglitazar Thiazolidinedione Glycemic control β-cell function Drug safety
摘 要：BACKGROUND Chiglitazar is an emerging pan-agonist of all peroxisome proliferator activated receptors(PPAR)-α,δandγ,and has therapeutic potential for type 2 diabetes(T2D).However,to date,no clinical studies or meta-analyses have compared the efficacy and safety of chiglitazar and traditional PPAR-γagonist thiazolidinediones(TZDs).A meta-analysis concerning this topic is therefore *** To compare the efficacy and safety of chiglitazar and TZD in patients with *** PubMed,Medline,Embase,the Cochrane Central Register of Controlled Trials,Reference Citation Analysis and *** websites were searched from August 1994 to March *** controlled trials(RCTs)of chiglitazar or TZD vs placebo in patients with T2D were *** comparisons and sensitivity analyses were implemented to evaluate multiple efficacy and safety endpoints of *** We included 93 RCTs that compared TZD with placebo and one that compared chiglitazar with *** efficacy endpoints,the augmented dose of chiglitazar resulted in greater reductions in hemoglobin(Hb)A1c[weighted mean difference(WMD)=-0.15%,95%confidence interval(CI):-0.27 to-0.04%],triglycerides(WMD=-0.17 mmol/L,95%CI:-0.24 to-0.11 mmol/L)and alanine aminotransferase(WMD=-5.25 U/L,95%CI:-8.50 to-1.99 U/L),and a greater increase in homeostasis model assessment-β(HOMA-β)(WMD=17.75,95%CI:10.73-24.77)when compared with TZD *** safety endpoints,the risks of hypoglycemia,edema,bone fractures,upper respiratory tract infection,urinary tract infection,and weight gain were all comparable between the augmented dose of chiglitazar and *** patients with baseline HbA1c≥8.5%,body mass index≥30 kg/m^(2)or diabetes duration10 years,the HbA1c reduction and HOMA-βincrease were more conspicuous for the augmented dose of chiglitazar compared with *** Augmented dose of chiglitazar,a pan-activator of PPARs,may serve as an antidiabetic agent with preferable glycemic and lipid control
维普期刊数据库